Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
Jian-wei Chen, Shu-qin Xie Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China Objective: Depressive and anxiety symptoms could affect the quality of life and prognostic outcomes in chronic kidney disease (CKD) patients, but only a few studies...
Guardado en:
Autores principales: | Chen JW, Xie SQ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2f923fd7c80f45358b16c470412526a7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial
por: Che T, et al.
Publicado: (2018) -
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
por: Daniel Cejka
Publicado: (2021) -
High Unawareness of Chronic Kidney Disease in Germany
por: Susanne Stolpe, et al.
Publicado: (2021) -
Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE
por: Medvedev VE
Publicado: (2017) -
Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report
por: Igata R, et al.
Publicado: (2016)